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Pre-treatment clinical features in central
retinal vein occlusion that predict visual
outcome following intravitreal ranibizumab
Kerr Brogan1* , Monica Precup2, Amanda Rodger2, David Young3 and David Francis Gilmour1
Abstract
Background: Predicting how patients with central retinal vein occlusion (CRVO) will respond to intravitreal anti-
VEGF is challenging. The purpose of this study was to identify pre-treatment clinical features in CRVO that predict
visual acuity (VA) following intravitreal ranibizumab.
Methods: Medical records, fundus images and optical coherence tomography (OCT) scans of treatment naïve
patients with CRVO receiving PRN intravitreal ranibizumab were retrospectively reviewed. Early Treatment Diabetic
Retinopathy Study (ETDRS) VA and central retinal thickness (CRT) were recorded at baseline, 3 and 12 months after
starting therapy. Regression analysis was used to determine independent predictors of VA at 3 and 12 months
follow-up. Possible predictors included baseline VA, age, presence of cotton wool spots (CWS), haemorrhages (few
scattered or multiple deep), foveal detachment, CRT, time from presentation to treatment, number of injections
given, presence of RAPD, and cause of CRVO.
Results: Data from 52 eyes of 50 patients receiving intravitreal ranibizumab treatment for CRVO were analyzed. The
mean pre-treatment VA was 43.3 (SD 22.5) letters, which improved to 52.0 (SD 24.3) letters at 3 months, then dropped to
42.0 (SD 30.26) at 12 months. Baseline CRT reduced from 616.7 μm (SD 272.4) to 346.0 μm (SD 205.2) at 3 months and
304.0 μm (SD 168.3) at 12 months. The following features were predictive of poorer VA after starting intravitreal
ranibizumab: Poorer pretreatment VA (3-months, P = 0.010; 12-months, P = 0.006), increasing age (3-months, P = < 0.001;
12-months, P = 0.006), and presence of CWS (3-months, P < 0.001; 12-months, P = 0.045).
Conclusion: Pre-treatment VA, older age, and presence of CWS are easily identifiable clinical features in the
hospital setting which help predict visual outcome in patients with CRVO receiving intravitreal ranibizumab.
Keywords: Retina, Central retinal vein occlusion, Anti-VEGF, Ranibuzimab
Background
Central retinal vein occlusion (CRVO) is the second
most common cause of visual impairment due to retinal
vascular disease in the UK after diabetic retinopathy [1],
with prevalence ranging from 0.1 to 0.5% [2, 3]. It occurs
when there is thrombosis of the central retinal vein as it
passes through the lamina cribosa of the optic nerve [2].
Optic disc oedema, increased dilatation and tortuosity of
all retinal veins, widespread deep and superficial hae-
morrhages, cotton wool spots (CWS), and retinal
oedema are classic clinical features of this condition.
Visual deterioration in CRVO is due to a combination of
macular oedema and macular ischaemia. The former
results from ischaemic retina producing abnormally high
levels of intra-ocular vascular endothelial growth factor
(VEGF) leading to vascular leakage. Anti-VEGF treat-
ments, including ranibizumab and aflibercept, have been
shown to be safe and effective in large randomized con-
trolled trials (RCTs) and have been approved by the
regulatory authorities across the globe [3–6]. In more
severe CRVO, however, there is greater retinal ischaemia
and predicting clinical outcomes from intravitreal anti-
VEGF therapy in these patients is challenging. The Royal
College of Ophthalmologists (RCO) retinal vein
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occlusion guidelines describe a number of clinical fea-
tures that can be used to assess the level of retinal
ischaemia in CRVO. These include: poor visual acuity;
presence of a relative afferent pupillary defect (RAPD);
multiple dark deep intra-retinal haemorrhages; multiple
CWS; retinal vein dilatation and tortuosity; fluorescein
angiography (FFA) showing greater than 10 disc areas of
retinal capillary non-perfusion on 7-field FFA; and
electroretinogram (ERG) showing reduced b wave
amplitude, reduced b:a ratio, and prolonged b-wave
implicit time [1]. In the hospital service setting, however,
ERG is not performed as part of routine practice and
FFA carried out at presentation is often unreliable in
detecting capillary non-perfusion due to masking from
retinal haemorrhages. Furthermore, The RCO guidelines
concluded that there was no evidence as to which clin-
ical feature or combination of features best defines
ischaemic CRVO.
The paucity of evidence for the treatment of severe is-
chaemic CRVO, together with the difficulties in accur-
ately measuring levels of retinal ischaemia, make it
difficult for the clinician to decide whether to treat pa-
tients presenting with CRVO on the severe end of the
spectrum. The aim of this study was to identify clinical
features of CRVO, readily available in the eye clinic at
first presentation, which can be used to predict outcome
following intravitreal anti-VEGF therapy.
Methods
Clinical records of treatment naive patients with CRVO
receiving a PRN treatment regime of intravitreal ranibi-
zumab therapy from 2009 to 2015 across three hospitals
in Glasgow were retrospectively reviewed. The Optical
Coherence Tomography (OCT) and fundal images that
were analyzed were captured using the TopCon OCT-
2000 (Topcon, Tokyo, Japan). This is a standard imaging
system which captures spectral domain OCT images and
a 30 degree posterior pole colour fundus image.
Regression analysis was used to determine independ-
ent predictors of ETDRS at 3 and 12 months after start-
ing anti-VEGF therapy. Possible predictors were pre-
treatment VA (ETDRS), age, presence of CWS (Fig. 1),
presence of multiple deep retinal haemorrhages (Fig. 2)
versus few scattered haemorrhages (Fig. 3), foveal de-
tachment, central retinal thickness (CRT), length of time
from presentation to first injection, number of injec-
tions, presence of RAPD and cause of CRVO. Variables
which were significant in the final model at a 5% signifi-
cance level were selected by backward regression ana-
lysis using Minitab (version 17). The majority of the VA
measurements were recorded using Early Treatment
Diabetic Retinopathy Study (ETDRS) letter score, how-
ever a small number were recorded in Snellen visual
acuity. Snellen measurements were converted to ETDRS
letter score using a recognized method [7].
Adhering to the West of Scotland Research Ethics
Service review, ethics approval was not required for this
study. This research has followed the Tenets of the
Declaration of Helsinki.
Results
Clinical data from 52 eyes of 50 patients who received
intra-vitreal ranibizumab for CRVO were analyzed.
Twenty three patients were female (46%) and 27 male
(54%). The mean age at treatment was 72 years (SD
12.7). Forty-seven patients had a common vascular risk
factor (hypertension, diabetes, hypercholesterolaemia or
smoking). Of the remaining three patients without a rec-
ognized vascular risk, two had retinal vasculitis and one
had co-existing ocular hypertension. Follow up was
Fig. 1 Fundus image from TopCon OCT-2000 showing cotton
wool spots
Fig. 2 Fundus image from TopCon OCT-2000 showing multiple
deep dark haemorrhages
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100% at 3 months and 92% at 12 months (four patients
were lost to follow up).
The mean pre-treatment VA was 43.3 (SD 22.5)
ETDRS letters, which improved to 52.0 (SD 24.3) letters
at 3 month, and dropped to 42.0 (SD 30.26) at 12 months
after starting treatment. The mean number of intra-
vitreal ranibuzimab injections was 2 (SD 1) at 3 months
and 4 (SD 2) at 12 months. Nine cases (17.3%) had a
pre-treatment VA of less than 20 letters (Snellen equiva-
lent 3/60). The mean time from presentation to first
injection was 29.2 days (SD 48.1, range 0–199 days).
Eight eyes (15%) developed rubeosis over the course of
treatment, three of which discontinued treatment at 3
months and seven by 12 months. CRT was available on
OCT scan images in 42 of 52 (80.7%), 47 of 52 (90.4%),
and 40 of 48 (83.3%) eyes at baseline, 3 and 12 months
respectively. CRT reduced from 616.7 (SD 272.4) at
baseline to 345.7 (SD 205.2) and 304.5 (SD 168.3) at 3
and 12 months respectively. Forty-five of 52 eyes (86.5%)
had available OCT and clinical images of suitable quality
for analysis of CWS, retinal haemorrhages and foveal
detachment. Presence of RAPD was only available in
clinical records of 8/52 cases. As the predominant cause
of CRVO was common vascular risk factors (94.2%) this
did not allow adequate comparison with other causes of
CRVO in our data set. For these reasons presence of
RAPD and cause of CRVO were not included in the
regression analysis. Table 1 summarizes VA outcomes
categorised by pretreatment clinical features.
Regression analysis showed that poorer baseline VA
(p = 0.010), older age (p < 0.001) and presence of CWS
(p < 0.001) predicted poorer VA at 3 months after start-
ing intravitreal ranibizumab. Increasing age (p = 0.006)
and poorer VA at 3 months (p < 0.001) predicted poorer
VA at 12 months follow up. Univariate analysis showed
presence of CWS to also be associated with poorer VA
at 12 months (P = 0.045), however, this was less predict-
ive than pre-treatment VA and age. Deep dark haemor-
rhages, foveal detachment, CRT, length of time from
presentation to treatment, and number of ranibizumab
injections received were not predictive of VA at 3 or
12 months follow up (Table 2).
Discussion
Intravitreal anti-VEGF therapy was first included in
treatment regimes for macular oedema secondary to
CRVO around 10 years ago [8]. Bevacizumab showed
promising results correlating reduction in macular
oedema with improved visual acuity [8, 9]. In 2007, rani-
bizumab was licenced by the European Medicines
Agency (EMA) for use in RVO patients following the
pivotal BRAVO and CRUISE clinical trials [3, 4]. Five
years later aflibercept was licensed for CRVO following
the COPERNICUS and GALILEO clinical trials [5, 6].
The benefits from treating non-ischaemic CRVO have
been well documented in these studies, however, visual
outcome in ischaemic CRVO is much harder to predict.
Accurately quantifying retinal ischaemia in CRVO is
critical in the assessment of the disease. The methods of
measuring ischaemia, however, are varied and not uni-
versally agreed. Hayreh et al. identified high-risk charac-
teristics in CRVO patients who developed
neovascularisation (NV) [10]. These criteria included
best corrected visual acuity (BCVA) ≤ 6/60, loss of the
1-2e isopter on Goldmann visual field, RAPD ≥0.9 log
units determined by neutral density filters, and electro-
retinogram reduction to ≤60% of corresponding A-wave.
The Central Retinal Vein Occlusion Study (CVOS)
group conducted the first major clinical trials to measure
retinal ischaemia [11, 12]. Patients were deemed to be
ischaemic if they had ≥10 disc areas of non-perfusion on
FFA. These criteria were subsequently used in CRUISE,
GALILEO and COPERNICUS [4–6] studies. Using 7-
field fundus photography for FFA, however, only cap-
tures one third of the retinal surface. With the advent of
wide field FFA, attempts have now been made to meas-
ure global retinal ischaemia in CRVO patients. Tsui et al.
created the ischaemic index method, whereby areas of
non-perfusion on wide field FFA were marked and
expressed as a percentage of total visible retina [13].
Similarly, Nicholson et al. used concentric rings to meas-
ure topographic areas of non-perfusion on wide field
FFA and correlated areas of non-perfusion with NV
development [14]. Despite these advances, identifying
ischaemic CRVO with FFA in the acute presentation of
CRVO still has its challenges. Up to one third of
patient’s FFAs are inadequately assessed due to masking
from retinal haemorrhages or media opacities [10]. Iso-
lated macular ischaemia may also be missed because
assessment of the perifoveal vasculature is not possible
Fig. 3 Fundus image from TopCon OCT-2000 showing few
scattered haemorrhages
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in 11% of cases [15]. Additionally, retinal capillary clos-
ure can progress up to 3 months from onset of CRVO,
therefore early FFA may underestimate the extent of
retinal ischaemia at presentation [10, 15, 16]. ERG is an
alternative method for measuring global ischaemia in
CRVO [17]. Reduced b wave amplitude, reduced b:a
ratio and prolonged b-wave implicit time are common
findings that indicate retinal ischemia [18–21]. Although
helpful in a research setting, ERG is not routinely carried
out in all hospital settings. Visual fields (VF), on the
other hand, are more readily available in the ophthal-
mology clinic, but not routinely used in assessment of
CRVO patients. Hayreh et al. emphasized the import-
ance of measuring peripheral retinal function with Gold-
man VF instead of focusing on VA alone [22]. VA,
although being poor in global ischaemia, can also be
reduced in isolated macular ischaemia. Trying to
distinguish isolated macular ischaemia from global
ischaemia in CRVO with the above investigations is
important as the former carries a better prognosis [23].
Evidently, findings on FFA, ERG, and VF help identify
retinal ischaemia, however, they are not always reliable
and have to be analyzed in conjunction with clinical fea-
tures. In recently published guidelines, the RCO con-
cluded that there was no evidence as to which clinical
feature or combination of features best defines ischaemic
CRVO [1].
In this study we aimed to move away from the trad-
itional classification of CRVO into ischaemic and non-
ischaemic, and move towards identifying factors that can
help predict the clinical outcome following anti-VEGF
treatment. Longer duration of CRVO, poorer baseline
VA, and older age have all been shown to predict poorer
visual outcome in patients with CRVO undergoing anti-
VEGF treatment [24–31]. Our study corroborates with
the latter two features. To complement this literature,
our study also found presence of CWS to be associated
with poorer vision in CRVO patients undergoing anti-
VEGF treatment. CWS are accumulation of cytoid bod-
ies secondary to disruption to retinal axoplasmic flow,
and tend to occur at the border of ischaemic retina [32].
If there are CWS at the posterior pole then there is likely
to be a degree of adjacent retinal/macular ischaemia.
CWS, along with baseline VA and patient age, are easily
identifiable clinical features in CRVO which predict
poorer response to treatment. Baseline and follow-up
OCT images, however, also have a role in assessing vis-
ual prognosis. Increasing macular thickness and pre-
dominantly intra-retinal fluid (instead of sub-retinal
fluid) are associated with poorer vision following anti-
VEGF. Despite successful treatment of macular oedema,
if there is persistent disruption of external limiting
Table 2 Univariate analysis of predictors of poorer VA at 3 and
12 months after starting intravitreal ranibizumab in patients
with CRVO
3 months (P value) 12 months (P value)
Poorer baseline VA < 0.001 0.007
Increasing age < 0.001 < 0.001
Presence of CWS 0.004 0.045
Deep dark haemorrhages 0.362 0.535
Foveal detachment 0.463 0.728
Increasing CRT 0.143 0.056
Time from presentation to IVT 0.199 0.529
Number of injections 0.859 0.949
VA visual acuity, CRVO central retinal vein occlusion, CWS cotton wool spots,
CRT central retinal thickness, IVT intravitreal therapy
Table 1 Mean VA at baseline, 3 and 12 months following ranibizumab in CRVO patients categorised by pre-treatment clinical features
Pre-treatment clinical features Mean VA ± SD (ETDRS letters)
N (%) Pre-Treatment 3 Months 12 Months
Base line VA (ETDRS letters) > 59 14 (27%) 64.6 ± 6.0 64.1 ± 18.5 54.8 ± 26.3
40–59 23 (44%) 49.8 ± 5.3 57.4 ± 17.0 45.2 ± 30.5
20–39 6 (12%) 32.8 ± 6.6 36.3 ± 20.4 30.8 ± 18.5
0–19 9 (17%) 0.6 ± 1.7 28.0 ± 31.4 21.2 ± 31.6
Age (years) ≥75 26 (50%) 40.3 ± 24.3 40.0 ± 24.5 24.7 ± 27.8
< 75 26 (50%) 46.3 ± 20.5 63.3 ± 18.1 59.3 ± 21.8
CWS Yes 26 (58%) 38.0 ± 25.5 40.8 ± 26.1 31.3 ± 30.4
No 19 (42%) 48.2 ± 20.2 61.5 ± 17.1 49.6 ± 24.9
Haemorrhages Multiple Deep Dark 29 (58%) 37.9 ± 25.7 45.8 ± 26.6 36.8 ± 30.7
Few Scattered 19 (38%) 47.6 ± 19.4 53.0 ± 21.0 42.8 ± 28.1
None 2 (4%) 60.0 ± 21.2 72.5 ± 17.7 27.5 ± 38.9
Foveal Detachment Yes 28 (62%) 46.0 ± 22.9 48.4 ± 24.9 40.6 ± 28.5
No 17 (38%) 38.2 ± 22.8 53.8 ± 21.7 37.4 ± 30.3
VA Visual acuity, SD Standard deviation, ETDRS Early Treatment Diabetic Retinopathy Study, N number of eyes, CWS cotton wool spots
Brogan et al. BMC Ophthalmology  (2018) 18:37 Page 4 of 7
membrane and ellipsoid zone, visual gains are signifi-
cantly poorer [26]. On the other hand, if there is pre-
served foveal depression on OCT then visual outcome is
more promising [33]. In our study we looked at foveal
detachment as a potential prognostic factor in CRVO,
however, we found no significant correlation with VA
after treatment. Another important feature when asses-
sing OCT scans of CRVO patients is choroid thickness;
increased choroidal thickness predicts better functional
response from anti-VEGF [29]. Clearly there is a collec-
tion of prognostic clinical and OCT features of CRVO
emerging in the literature. In clinical practice, these
should be actively looked for when considering anti-
VEGF treatment.
When treating CRVO with intravitreal ranibuzimab,
the CRUISE study suggests that we can expect almost
50% of patients to gain 15 ETDRS letters or greater at
6 months follow up [4]. So why are our results not to
living up this standard? Our study included CRVO
patients with a full range of disease severity, including
patients who later developed neovascularisation. Our
broader phenotypic range of patients, although having
poorer visual gains, may be more representative of real
world data. Wai et al. reported similar short term results
in their real world study with an average letter gain of
9.6 letters at 6 months compared to 8.7 letters at
3 months in our cohort [31]. At 12 months, however,
our average VA drops to 42 ETDRS letters, which is 1.3
letters below average baseline VA. The eight patients
(15% of our cohort) included in our analysis who
became rubeotic at 12 months may account for the drop
in average VA. Another contributing factor is that we
may have been under-treating our patients. Our average
number of ranibuzimab injections at 12 months was 4
(SD 2). This is slightly lower than six injections reported
by Wai et al. [31]. In the CRUISE study, however,
patients were consistently receiving monthly injections
[4]. Our patients were treated on a PRN basis, and in
our earlier use of anti-VEGF some patients did not
receive 3 monthly injections as a loading dose. This, in
conjunction with patients not adhering to strict monthly
follow up in the NHS setting may explain the lower
injection rate and inefficiency of ranibuzimab. On the
other hand, number of injections in our data analysis did
not significantly influence VA in our cohort.
If a patient with CRVO is thought to have significant
retinal ischaemia, should we still be offering anti-VEGF
treatment? The RCO guidelines state that macular
oedema in eyes with ischaemic CRVO should be treated
in the same way as those with non-ischaemic CRVO [1].
With little supporting published evidence in this area,
treatment of ischaemic CRVO patients remains contro-
versial. The RAVE study set out to assess whether rani-
bizumab could alter the natural history of CRVO in high
risk eyes with three out of four Hayreh criteria [34].
Twenty patients received monthly ranibizumab for
9 months followed by 3 months of observation then
monthly PRN injections for 24 months. Nine patients
completed the full 36 months of treatment. The mean
ETDRS letters gained was 21.4. As the patient numbers
were small in this study and there was a large range of
visual change following treatment (− 23 to + 74 letters),
the secondary outcome finding should be viewed with
caution. With regards to the primary outcome measure,
this study demonstrated that NV formation was only
delayed and not prevented [34]. The question on
whether to treat patients with global retinal ischaemia
has also been addressed in two recent reviews. Ford
et al. concluded that the treatment benefits of
intravitreal anti-VEGF therapy are only likely to apply to
patients with non-ischaemic CRVO and that there are
no proven treatments available for established ischaemic
CRVO [35]. This was further corroborated by Gerding
et al. who stated that ranibizumab is generally not
recommended for patients presenting with irreversible
ischaemic visual loss because of the limited availability
of phase 3 trial data in this patient population [36]. This
review did, however, recommend considering ranibuzi-
mab when macular oedema is present in perfused retinal
areas adjacent to macular ischaemic retinal zones,
because some patients may experience a benefit. Based
on our study and recently published data, younger
patients are more likely to gain vision following anti-
VEGF in ischaemic CRVO, and should therefore be
offered treatment more readily [27].
Patients with CRVO are a heterogenous group and
clinical outcomes, particularly in patients with more
severe CRVO, are extremely difficult to predict. In-
stead of classifying patients into ischaemic and non-
ischaemic groups, our study focuses on identifying
clinical features in CRVO that predict poorer visual
outcome from intravitreal anti-VEGF therapy. Our re-
sults complement the current knowledge base in this
field and will help guide patients and doctors when
deciding on whether to commence treatment. We
hope other researchers will use our methodology for
future studies to uncover other clinical features that
may be important.
Conclusion
Poorer pre-treatment VA, older age, and presence of
CWS on standard 30 degree fundus photography
predict poorer visual outcomes in patients with
macular oedema secondary to CRVO receiving intra-
vitreal ranibizumab. This information can be used
during the consultation to help council patients on
the likelihood of achieving good visual recovery if
they opt for treatment.
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